Merck R&D: A Jam-Packed Pipeline, But Much Of It Is Wait-And-See
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With Schering-Plough's research now tucked snugly in with Merck's, the combined company met with analysts and investors for its widely anticipated R&D overview May 11. Even as management laid out a deep mid- to late-stage pipeline especially rich in cardiovascular products, executives provided little in the way of scientific news
You may also be interested in...
Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs
As Merck heads into a “patent cliff” year, highlights of its analyst meeting included updates on key Phase III drugs, growth in emerging markets, and unveiling of new programs in Alzheimer’s disease and diabetes.
Merck Likes Biosimilars, But Not ESAs
Merck is dropping development of one of its first biosimilar drug candidates, a pegylated version of Amgen's erythropoiesis stimulating agent Aranesp (darbepoetin alfa), due to cardiovascular risks associated with the drugs and potential regulatory requirements
Merck Likes Biosimilars, But Not ESAs
Merck is dropping development of one of its first biosimilar drug candidates, a pegylated version of Amgen's erythropoiesis stimulating agent Aranesp (darbepoetin alfa), due to cardiovascular risks associated with the drugs and potential regulatory requirements